Revelation Biosciences, Inc. REVB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001810560


None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $11.6M
Warnings	thin data not computable: dilution, degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Feb 26, 2026 249 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$4.00 2026-10-30; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury ("AKI") and GEM-CKD as a treatment for chronic kidney disease ("CKD"). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California. Our common stock and warrants sold in our initial public offering ("Public Warrants") are listed on The Nasdaq Stock Market, LLC ("Nasdaq") under the ticker symbol "REVB" and "REVBW," respectively.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 53.7						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(7.1%)	(6.6%)	53.7	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 48.7					
Twelve-month failure probability	not computable	0.08%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(10.76)	(0.35)	63.9	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
required facts have no common fiscal period end					
Current ratio	5.41x	2.92x	33.4	829	2025-12-31
Growth and financing, sleeve percentile 16.3					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
required facts have no common fiscal period end					
Asset growth, three years	28.2%	2.2%	16.3	696	2025-12-31
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(83.7%)	(2.2%)	4
Distance from 52-week high	(25.7%)	(28.7%)	54
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.98)	(0.19)	4

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$11.5M
Operating cash flow, four quarters	-$9.3M
Months of runway	14.8
Days since last periodic filing	88 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$28,171

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$8.9M	2025-12-31	2026-02-26	10-K	26-076552
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.3M	2025-12-31	2026-02-26	10-K	26-076552
3	assets	us-gaap:Assets	$11.6M	2025-12-31	2026-02-26	10-K	26-076552
4	assets	us-gaap:Assets	$6.6M	2024-12-31	2026-02-26	10-K	26-076552
5	current assets	us-gaap:AssetsCurrent	$10.8M	2025-12-31	2026-02-26	10-K	26-076552
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.0M	2025-12-31	2026-02-26	10-K	26-076552
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$49.4M	2025-12-31	2026-02-26	10-K	26-076552
8	operating income	us-gaap:OperatingIncomeLoss	-$9.1M	2025-12-31	2026-02-26	10-K	26-076552
9	book equity	us-gaap:StockholdersEquity	$8.9M	2025-12-31	2026-02-26	10-K	26-076552
10	liabilities	us-gaap:Liabilities	$2.7M	2025-12-31	2026-02-26	10-K	26-076552
11	assets	us-gaap:Assets	$12.2M	2023-12-31	2025-03-06	10-K	25-034584
12	assets	us-gaap:Assets	$5.5M	2022-12-31	2024-09-23	10-K/A	24-108793

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.